Conshohocken’s Cencora is not sitting still, writes John George for The Philadelphia Business Journal.
The Fortune 10 healthcare giant is making moves that signal a fundamental shift in how one of America’s largest companies sees its future.
The latest: the appointment of Eva C. Boratto as its new chief financial officer, a hire that arrives at a moment when Cencora is spending billions to redefine what kind of company it wants to be.
Boratto’s appointment takes effect June 29. She steps into the role as Cencora executes one of the most aggressive acquisition strategies in its history.
CEO Robert P. Mauch described her as “a purpose-driven executive with deep healthcare experience and strong financial and operational expertise,” language that points directly at where the company is headed.
That direction is increasingly clear. Cencora has been moving decisively beyond its roots in pharmaceutical logistics and distribution, placing enormous bets on specialty healthcare services instead.
The deals tell the story. In late 2024, Cencora acquired Retina Consultants of America for $4.6 billion. The move established it as a major force in retina care overnight.
In March, it agreed to purchase EyeSouth Partners’ retina business for another $1.1 billion, folding those physicians into the RCA network. And in December 2025, the company announced a definitive agreement to acquire a majority stake in OneOncology.
The physician-led network of independent oncology has practices based in Nashville. The deal is valued at approximately $5 billion. It was expected to close by the end of the first quarter of 2026.
Together, the acquisitions represent something more than a growth strategy. They represent a company that has decided pharmaceutical distribution, however lucrative, is not enough.
The scale of Cencora’s ambition is easier to grasp when you look at the numbers behind it. The company posted $321.3 billion in revenue and $1.55 billion in net income during fiscal 2025. It employs roughly 1,100 people in the Philadelphia region and more than 46,000 worldwide.
It is, by almost any measure, one of the most consequential companies headquartered in the Philadelphia suburbs, and it is growing more consequential by the quarter.
For Montgomery County, that is not a small footnote. One of the ten largest companies in America by revenue is based in Conshohocken, and it is in the middle of transforming itself into something the healthcare industry has not quite seen before.
To read more about Cencora’s future and the appointment of Eva C. Boratto in The Philadelphia Business Journal.
